44 unknown. 44 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Unknown 44 |
| Phase 1 | 7 | Unknown 7 |
| Phase 3 | 1 | Unknown 1 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy Vorolanib Tablets, Sintilimab Injection - Renal Cell Carcinoma, Immunotherapy | Phase 2 | Unknown | Hao Zeng | 67 | 2024-08-01 | 2024-07-26 |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer HAIC, Surufatinib, Tislelizumab - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 41 | 2023-11-01 | 2023-11-18 |
| Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Toripalimab - Cervical Cancer, Induction Chemotherapy | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2023-11-01 | 2025-03-11 |
| Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence SBRT, Chemotherapy, PD-1 antibody - Radiotherapy, Immunotherapy | Phase 2 | Unknown | Fudan University | 80 | 2023-09-25 | 2023-11-07 |
| Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Tisleizumab(BGB-A317) - DMMR Colorectal Cancer, Anti PD-1 | Phase 2 | Unknown | Sun Yat-sen University | 40 | 2023-09-23 | 2024-02-16 |
| Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC low-dose involved-field radiotherapy combined with immunochemotherapy - Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy | Phase 2 | Unknown | Sichuan University | 41 | 2023-08-24 | 2024-12-03 |
| Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Envafolimab, CAPEOX - Colon Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Sun Yat-sen University | 55 | 2023-07-01 | 2024-04-12 |
| Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Disitamab Vedotin combined with fruquintinib and Tislelizumab - HER2-positive Gastric Cancer, Immunotherapy | Phase 1 / Phase 2 | Unknown | Fudan University | 43 | 2023-05-09 | 2023-08-09 |
| Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers Terelizumab, CapeOx - Colon Cancer, Immunotherapy | Phase 2 | Unknown | fan li | 100 | 2023-05-01 | 2023-04-27 |
| Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC Cadonilimab - Immunotherapy, Second-line Treatment | Phase 2 | Unknown | Second Affiliated Hospital of Zunyi Medical University | 30 | 2023-01-01 | 2023-06-18 |
| Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer Durvalumab, Lenvatinib Oral Product, Chemotherapy - Biliary Tract Neoplasms, Immunotherapy | Phase 2 | Unknown | Peking Union Medical College Hospital | 40 | 2022-12-14 | 2023-11-15 |
| Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients Paclitaxel-albumin, Cisplatin, Carboplatin - Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes | Phase 2 | Unknown | Guangdong Provincial People's Hospital | 50 | 2022-11-30 | 2022-11-28 |
| Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer Toripalimab, Conventional segmental radiotherapy, opreation - Non-small Cell Lung Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Northern Jiangsu People's Hospital | 20 | 2022-08-08 | 2023-10-04 |
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy | Phase 2 / Phase 3 | Unknown | Taizhou Hospital | 60 | 2022-07-01 | 2023-04-18 |
| Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric Envafolimab - Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 35 | 2022-05-30 | 2022-05-24 |
| TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer Tislelizumab, bevacizumab, TAS-102 - Immunotherapy, Colorectal Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 25 | 2022-04-01 | 2022-08-23 |
| SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma sintilimab, Trastuzumab, S-1 plus oxaliplatin - HER2-positive, Locally Advanced Solid Tumor | Phase 2 | Unknown | Aiping Zhou | 44 | 2022-04-01 | 2022-04-06 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Camrelizumab plus Concurrent chemoradiotherapy - Cervical Carcinoma, Chemoradiotherapy | Phase 2 | Unknown | Lei Li | 92 | 2022-03-27 | 2022-04-13 |
| A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W) - Gastric Cancer, Chemotherapy | Phase 2 | Unknown | Jiuda Zhao | 31 | 2022-02-15 | 2022-04-11 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (3) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Nasopharyngeal Carcinoma (3) · Uterine Cervical Neoplasms (3) · Biliary Tract Neoplasms (2) · Carcinoma, Renal Cell (2) · Esophageal Squamous Cell Carcinoma (2) · Hypopharyngeal Neoplasms (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1)
Neoplasms (34) · Neoplasms by Site (33) · Digestive System Diseases (17) · Digestive System Neoplasms (17) · Gastrointestinal Diseases (13) · Gastrointestinal Neoplasms (12) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Carcinoma (10) · Head and Neck Neoplasms (10) · Intestinal Diseases (7) · Intestinal Neoplasms (7) · Colonic Diseases (6) · Otorhinolaryngologic Diseases (6) · Pharyngeal Diseases (6)
camrelizumab (8) · tislelizumab (7) · sintilimab (6) · toripalimab (5) · Drug Therapy (4) · Radiotherapy (4) · Cisplatin (3) · apatinib (3) · Carboplatin (2) · Immunotherapy (2) · Oxaliplatin (2) · S 1 (combination) (2) · Surgical Procedures, Operative (2) · anlotinib (2) · envafolimab (2)
Sun Yat-sen University (7) · Fudan University (3) · Peking University First Hospital (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Lei Li (2) · Shanghai Changzheng Hospital (2) · Tianjin Medical University Cancer Institute and Hospital (2) · West China Hospital (2) · Aiping Zhou (1) · Asan Medical Center (1) · Central Adelaide Local Health Network Incorporated (1) · Eye & ENT Hospital of Fudan University (1) · First Affiliated Hospital of Zhejiang University (1) · Fujian Cancer Hospital (1) · Guangdong Provincial People's Hospital (1)
China (38) · Australia (1) · South Korea (1)
Lei Li, M.D. (2) · Tao Zhang, MD (2) · Xianshu Gao, MD,PhD (2) · Desheng Hu, Dr. (1) · Fan Xia, M.D,PH.D (1) · Gong Chen, Prof (1) · Guibin Qiao, MD (1) · Hao Zeng (1) · Hao Zeng, Doctor (1) · Hu Ma, Ph.D (1) · Jie Chen (1) · Junlin Yi, MD (1) · Liang Zhou, PhD. (1) · Ming Kuang, Ph.D. (1) · Ming Kuang, PhD (1)
PMID 34154614, PMID 34725214, PMID 35476700, PMID 35623069, PMID 36735896, PMID 38637772, PMID 38706247, PMID 38853265, PMID 39144362, PMID 39756446, PMID 40346524, PMID 40810951, PMID 41748259